The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)
Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Cze...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2020-07, Vol.99 (7), p.1583-1594 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1594 |
|---|---|
| container_issue | 7 |
| container_start_page | 1583 |
| container_title | Annals of hematology |
| container_volume | 99 |
| creator | Janikova, Andrea Michalka, Jozef Bortlicek, Zbynek Chloupkova, Renata Campr, Vit Kopalova, Natasa Klener, Pavel Benesova, Katerina Hamouzova, Jitka Belada, David Prochazka, Vit Pytlik, Robert Pirnos, Jan Duras, Juraj Mocikova, Heidi Trneny, Marek |
| description | Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts ( 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000–2017). At the time of relapse, the median age was 67 years (range 22–95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1–851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10–24.5%) vs. 20.5% (range 13.5–27.4%) vs. 42.2% (range 35.5–48.8%) for ITT 21 days (
p
|
| doi_str_mv | 10.1007/s00277-020-04099-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2417167842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2417167842</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-8c1604409d51c6d3ae6a1c757c01df8e82394db9fc9b1988f9ca59c2df71b4b53</originalsourceid><addsrcrecordid>eNp9kc9u3CAQh1HVSN0mfYGekHJJD24A22uTW7tqk5VWzaHpGY1h2CXxvwJu5Lxd3izsbqTcygVp9M3HMD9CPnP2lTNWXQbGRFVlTLCMFUzKbH5HFrzIRcbKunhPFkzmMivT-UA-hnDPGBd1IRbk-W6H1PUR_T9oaYPxEbGnox-2HkNwQ0-hNzTu0MM4J9BFB3FfdmFfpQ84H-h-CNFpOoKHDpMtodRjC2Nw_ZYaZ-0UkLbgt0i_U41tS9u5G3dDB1fpCWjnkIzWD91Bu3pCvaObV4L-jpOZ6bUfppEaiNBAkl38Wt-sN1_OyImFNuCn1_uU_Pn54251k21ur9erb5tM5yyPWa35khVpN6bkemlywCVwXZWVZtzYGmuRy8I00mrZcFnXVmoopRbGVrwpmjI_JedHb_ru3wlDVPfD5NPkQYmCV3xZpYUmShwp7YcQPFo1eteBnxVnah-VOkalUlTqEJWaU1N-bAoJ7rfo39T_6XoBvKObig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2417167842</pqid></control><display><type>article</type><title>The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)</title><source>SpringerLink Journals - AutoHoldings</source><creator>Janikova, Andrea ; Michalka, Jozef ; Bortlicek, Zbynek ; Chloupkova, Renata ; Campr, Vit ; Kopalova, Natasa ; Klener, Pavel ; Benesova, Katerina ; Hamouzova, Jitka ; Belada, David ; Prochazka, Vit ; Pytlik, Robert ; Pirnos, Jan ; Duras, Juraj ; Mocikova, Heidi ; Trneny, Marek</creator><creatorcontrib>Janikova, Andrea ; Michalka, Jozef ; Bortlicek, Zbynek ; Chloupkova, Renata ; Campr, Vit ; Kopalova, Natasa ; Klener, Pavel ; Benesova, Katerina ; Hamouzova, Jitka ; Belada, David ; Prochazka, Vit ; Pytlik, Robert ; Pirnos, Jan ; Duras, Juraj ; Mocikova, Heidi ; Trneny, Marek</creatorcontrib><description><![CDATA[Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts (< 7 vs. 7–21 vs. > 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000–2017). At the time of relapse, the median age was 67 years (range 22–95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1–851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10–24.5%) vs. 20.5% (range 13.5–27.4%) vs. 42.2% (range 35.5–48.8%) for ITT < 7 vs. 7–21 vs. > 21 days (
p
< 0.001). ITT was associated with B symptoms (
p
0.004), ECOG (
p
< 0.001), stage (
p
0.002), bulky disease (
p
0.005), elevated LDH (
p
< 0.001), and IPI (
p
< 0.001). The ITT mirrors the real clinical behavior of rDLBCL. There are patients (ITT < 7 days) with aggressive disease and a poor outcome. Conversely, there are rDLBCLs with ITT ≥ 21 days who survive for a long time.]]></description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-020-04099-y</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Hematology ; Lymphoma ; Medical prognosis ; Medicine ; Medicine & Public Health ; Oncology ; Original Article</subject><ispartof>Annals of hematology, 2020-07, Vol.99 (7), p.1583-1594</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c303t-8c1604409d51c6d3ae6a1c757c01df8e82394db9fc9b1988f9ca59c2df71b4b53</cites><orcidid>0000-0002-2647-7769</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-020-04099-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-020-04099-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Janikova, Andrea</creatorcontrib><creatorcontrib>Michalka, Jozef</creatorcontrib><creatorcontrib>Bortlicek, Zbynek</creatorcontrib><creatorcontrib>Chloupkova, Renata</creatorcontrib><creatorcontrib>Campr, Vit</creatorcontrib><creatorcontrib>Kopalova, Natasa</creatorcontrib><creatorcontrib>Klener, Pavel</creatorcontrib><creatorcontrib>Benesova, Katerina</creatorcontrib><creatorcontrib>Hamouzova, Jitka</creatorcontrib><creatorcontrib>Belada, David</creatorcontrib><creatorcontrib>Prochazka, Vit</creatorcontrib><creatorcontrib>Pytlik, Robert</creatorcontrib><creatorcontrib>Pirnos, Jan</creatorcontrib><creatorcontrib>Duras, Juraj</creatorcontrib><creatorcontrib>Mocikova, Heidi</creatorcontrib><creatorcontrib>Trneny, Marek</creatorcontrib><title>The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description><![CDATA[Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts (< 7 vs. 7–21 vs. > 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000–2017). At the time of relapse, the median age was 67 years (range 22–95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1–851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10–24.5%) vs. 20.5% (range 13.5–27.4%) vs. 42.2% (range 35.5–48.8%) for ITT < 7 vs. 7–21 vs. > 21 days (
p
< 0.001). ITT was associated with B symptoms (
p
0.004), ECOG (
p
< 0.001), stage (
p
0.002), bulky disease (
p
0.005), elevated LDH (
p
< 0.001), and IPI (
p
< 0.001). The ITT mirrors the real clinical behavior of rDLBCL. There are patients (ITT < 7 days) with aggressive disease and a poor outcome. Conversely, there are rDLBCLs with ITT ≥ 21 days who survive for a long time.]]></description><subject>Hematology</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc9u3CAQh1HVSN0mfYGekHJJD24A22uTW7tqk5VWzaHpGY1h2CXxvwJu5Lxd3izsbqTcygVp9M3HMD9CPnP2lTNWXQbGRFVlTLCMFUzKbH5HFrzIRcbKunhPFkzmMivT-UA-hnDPGBd1IRbk-W6H1PUR_T9oaYPxEbGnox-2HkNwQ0-hNzTu0MM4J9BFB3FfdmFfpQ84H-h-CNFpOoKHDpMtodRjC2Nw_ZYaZ-0UkLbgt0i_U41tS9u5G3dDB1fpCWjnkIzWD91Bu3pCvaObV4L-jpOZ6bUfppEaiNBAkl38Wt-sN1_OyImFNuCn1_uU_Pn54251k21ur9erb5tM5yyPWa35khVpN6bkemlywCVwXZWVZtzYGmuRy8I00mrZcFnXVmoopRbGVrwpmjI_JedHb_ru3wlDVPfD5NPkQYmCV3xZpYUmShwp7YcQPFo1eteBnxVnah-VOkalUlTqEJWaU1N-bAoJ7rfo39T_6XoBvKObig</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Janikova, Andrea</creator><creator>Michalka, Jozef</creator><creator>Bortlicek, Zbynek</creator><creator>Chloupkova, Renata</creator><creator>Campr, Vit</creator><creator>Kopalova, Natasa</creator><creator>Klener, Pavel</creator><creator>Benesova, Katerina</creator><creator>Hamouzova, Jitka</creator><creator>Belada, David</creator><creator>Prochazka, Vit</creator><creator>Pytlik, Robert</creator><creator>Pirnos, Jan</creator><creator>Duras, Juraj</creator><creator>Mocikova, Heidi</creator><creator>Trneny, Marek</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><orcidid>https://orcid.org/0000-0002-2647-7769</orcidid></search><sort><creationdate>20200701</creationdate><title>The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)</title><author>Janikova, Andrea ; Michalka, Jozef ; Bortlicek, Zbynek ; Chloupkova, Renata ; Campr, Vit ; Kopalova, Natasa ; Klener, Pavel ; Benesova, Katerina ; Hamouzova, Jitka ; Belada, David ; Prochazka, Vit ; Pytlik, Robert ; Pirnos, Jan ; Duras, Juraj ; Mocikova, Heidi ; Trneny, Marek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-8c1604409d51c6d3ae6a1c757c01df8e82394db9fc9b1988f9ca59c2df71b4b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Hematology</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Janikova, Andrea</creatorcontrib><creatorcontrib>Michalka, Jozef</creatorcontrib><creatorcontrib>Bortlicek, Zbynek</creatorcontrib><creatorcontrib>Chloupkova, Renata</creatorcontrib><creatorcontrib>Campr, Vit</creatorcontrib><creatorcontrib>Kopalova, Natasa</creatorcontrib><creatorcontrib>Klener, Pavel</creatorcontrib><creatorcontrib>Benesova, Katerina</creatorcontrib><creatorcontrib>Hamouzova, Jitka</creatorcontrib><creatorcontrib>Belada, David</creatorcontrib><creatorcontrib>Prochazka, Vit</creatorcontrib><creatorcontrib>Pytlik, Robert</creatorcontrib><creatorcontrib>Pirnos, Jan</creatorcontrib><creatorcontrib>Duras, Juraj</creatorcontrib><creatorcontrib>Mocikova, Heidi</creatorcontrib><creatorcontrib>Trneny, Marek</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Janikova, Andrea</au><au>Michalka, Jozef</au><au>Bortlicek, Zbynek</au><au>Chloupkova, Renata</au><au>Campr, Vit</au><au>Kopalova, Natasa</au><au>Klener, Pavel</au><au>Benesova, Katerina</au><au>Hamouzova, Jitka</au><au>Belada, David</au><au>Prochazka, Vit</au><au>Pytlik, Robert</au><au>Pirnos, Jan</au><au>Duras, Juraj</au><au>Mocikova, Heidi</au><au>Trneny, Marek</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><date>2020-07-01</date><risdate>2020</risdate><volume>99</volume><issue>7</issue><spage>1583</spage><epage>1594</epage><pages>1583-1594</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract><![CDATA[Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts (< 7 vs. 7–21 vs. > 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000–2017). At the time of relapse, the median age was 67 years (range 22–95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1–851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10–24.5%) vs. 20.5% (range 13.5–27.4%) vs. 42.2% (range 35.5–48.8%) for ITT < 7 vs. 7–21 vs. > 21 days (
p
< 0.001). ITT was associated with B symptoms (
p
0.004), ECOG (
p
< 0.001), stage (
p
0.002), bulky disease (
p
0.005), elevated LDH (
p
< 0.001), and IPI (
p
< 0.001). The ITT mirrors the real clinical behavior of rDLBCL. There are patients (ITT < 7 days) with aggressive disease and a poor outcome. Conversely, there are rDLBCLs with ITT ≥ 21 days who survive for a long time.]]></abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00277-020-04099-y</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2647-7769</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2020-07, Vol.99 (7), p.1583-1594 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_journals_2417167842 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Hematology Lymphoma Medical prognosis Medicine Medicine & Public Health Oncology Original Article |
| title | The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A11%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20interval%20between%20progression%20and%20therapy%20initiation%20is%20the%20key%20prognostic%20parameter%20in%20relapsing%20diffuse%20large%20B%20cell%20lymphoma:%20analysis%20from%20the%20Czech%20Lymphoma%20Study%20Group%20database%20(NIHIL)&rft.jtitle=Annals%20of%20hematology&rft.au=Janikova,%20Andrea&rft.date=2020-07-01&rft.volume=99&rft.issue=7&rft.spage=1583&rft.epage=1594&rft.pages=1583-1594&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-020-04099-y&rft_dat=%3Cproquest_cross%3E2417167842%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2417167842&rft_id=info:pmid/&rfr_iscdi=true |